Notice of Annual General Meeting in Biovitrum AB (publ),May 3, 2007
Notice of Annual General Meeting in Biovitrum AB (publ),May 3, 2007
The shareholders in Biovitrum AB (publ), reg no 556038-9321, are hereby summoned to the annual general meeting (the “Meeting”), to be held on Thursday 3 May 2007 at 4.00 p.m. in the lecture hall, Lindhagensgatan 133, Stockholm, Sweden. Participation, etc Shareholders who wish to attend the meeting must be recorded in the share register maintained by VPC AB (the Swedish Central Securities Depository) on Thursday 26 April 2007, and must notify the company of their intention to participate in the Meeting not later than 4.00 p.m. on Thursday 26 April 2007 at Biovitrum's web site www.biovitrum.com, by mail to Biovitrum AB (publ), “Annual General Meeting”, 112 76 Stockholm, Sweden or by phone no. +46 8 697 34 27. The notification shall set forth the name, address, telephone number (daytime), personal/corporate identity number, the number of shares held and, when applicable, information about representatives and assistants. Nominee shares Shareholders, whose shares have been registered in the name of a nominee through the trust department of a bank or similar institution, must temporarily re-register their shares in their own names in the shareholders' register maintained by VPC AB to be entitled to participate in the Meeting. Shareholders must inform their nominee of such re-registration well before Thursday 26 April 2007, when such re-registration must have been executed. Proxy, etc Shareholders represented by proxy shall issue a written and dated power of attorney for the proxy. If the power of attorney is issued on behalf of a legal entity, a certified copy of a registration certificate for the legal entity shall be appended. The power of attorney and the registration certificate may not be older than one year. The power of attorney in original and, when applicable, the registration certificate, should be submitted to the company by mail at the address indicated above well before the Meeting. Attachment: Notice of Annual General Meeting in Biovitrum AB (publ) 2007. For additional information, please contact: Biovitrum AB (publ) Mats Pettersson, CEO Phone: +46 8 697 23 27 mats.pettersson@biovitrum.com Anna Karin Källén, Vice President, Corporate Communications Phone: +46 8 697 20 85, cell phone: +46 73 433 20 85 annakarin.kallen@biovitrum.com About Biovitrum Biovitrum is one of the largest biopharma companies in Europe. With operations in Sweden and in the UK Biovitrum conducts research and develops pharmaceuticals for unmet medical needs both for common diseases and conditions that affect smaller patient populations. Biovitrum has a broad and balanced R&D portfolio with several projects in clinical and preclinical phases for the treatment of obesity, diabetes, inflammation and eye and blood diseases as well as a number of well defined niche indications. Biovitrum develops and produces protein-based drugs on a contractual basis and markets a range of specialist pharmaceuticals primarily in the Nordic countries. Biovitrum has revenues of approximately SEK 1.2 billion and 550 employees. Biovitrum is listed on the Stockholm Stock Exchange since September 15, 2006. For more information see www.biovitrum.com.